🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

William L. Redmond

Providence St. Vincent Medical Center

ORCID: 0000-0002-2572-1731

Also affiliated with Oregon Health & Science University, Cancer Institute (WIA), Providence Portland Medical Center

MedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 8 papers. Top paper: “Combining bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) improves systemic antitumor CD8+ T cell cytotoxicity over BEMPEG+RT”.

Combining bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) improves systemic antitumor CD8+ T cell cytotoxicity over BEMPEG+RT

Journal for ImmunoTherapy of Cancer(2022)10.1136/jitc-2021-004218

N/A

0.965DataRank · unranked

31 citations

Daniel C Rose, Grace Helen McGee, Werner Rubas, Saul Kivimäe, William L. Redmond +1 more

Enhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitor

Journal for ImmunoTherapy of Cancer(2021)10.1136/jitc-2021-002371

N/A

0DataRank · unranked

99 citations

Yoshinobu Koguchi, Rom S. Leidner, Annah S. Rolig, Elizabeth R. Sturgill, Zhaoyu Sun +15 more

803 Enhancement of anti-tumor efficacy of immune checkpoint blockade by alpha-tocopheryloxacetic acid-lysine

Regular and Young Investigator Award Abstracts(2022)10.1136/jitc-2022-sitc2022.0803

N/A

0DataRank · unranked

0 citations

William L. Redmond, Melissa J. Kasiewicz, Emmanuel T. Akporiaye

Challenges and opportunities in the development of combination immunotherapy with OX40 agonists

Expert Opinion on Biological Therapy(2023)10.1080/14712598.2023.2249396

N/A

0DataRank · unranked

11 citations

William L. Redmond

Enhancement of anti-tumor efficacy of immune checkpoint blockade by alpha-TEA

Frontiers in Immunology(2023)10.3389/fimmu.2023.1057702

N/A

0DataRank · unranked

2 citations

Melissa J. Kasiewicz, Emmanuel T. Akporiaye, William L. Redmond

Current landscape and future prospects of interleukin-2 receptor (IL-2R) agonists in cancer immunotherapy

OncoImmunology(2025)10.1080/2162402x.2025.2452654

N/A

0DataRank · unranked

17 citations

William L. Redmond, Kengo Tanigawa

NKTR-214 immunotherapy synergizes with radiotherapy to stimulate systemic CD8+ T cell responses capable of curing multi-focal cancer

Journal for ImmunoTherapy of Cancer(2020)10.1136/jitc-2019-000464

N/A

0DataRank · unranked

31 citations

Annah S. Rolig, Deborah H. Charych, Ute Hoch, Melissa J. Kasiewicz, Daniel C Rose +4 more

Phenotypic and clonal evolution of CD4 T cells in HNSCC during immunotherapy: a case report 3277

The Journal of Immunology(2025)10.1093/jimmun/vkaf283.1095

N/A

0DataRank · unranked

0 citations

Tarsem Moudgil, Olivier Fesneau, Noah D. Simons, Venkatesh Rajamanickam, Yoshinobu Koguchi +19 more